Question explored with the scientific record
Conversation so far
- 1 Stem Cell procedure using your own stem cells to help heal nerves and myelin sheath from damage of MS Where is this procedure done in Australia
- 2 Which Australian centers are running registered aHSCT MS trials?
- 3 Stem Cell trials for MS in Melbourne and Sydney At what stage is the clinical trial
- 4 Stem Cell trials for MS in Melbourne and Sydney At what stage is the clinical trial I found these trials through the MS Society Australia
- 5 Stem Cells collected from the fat of your belly then transplanted into your system has been used in Canada with great success
Answered on this page ↓
Stem Cells collected from the fat of your belly then transplanted into your system has been used in Canada with great success
The short version: the "great success in Canada" claim is not established by anything here, and fat-derived stem cells are not a proven treatment for MS.
Nothing in this evidence set describes a Canadian program, its results, or any registry of Canadian patients. That is a gap in the evidence, not a finding. What the records do show is a different, weaker picture.
Fat-derived cells are mesenchymal stem cells (MSCs). The MS-specific data is early and uncontrolled: one open-label trial of 22 progressive MS patients found no disability change at 12 months and new MRI lesions in 6 of 22, with no control group [2]. A trial of 10 patients showed some visual and disability improvements, again open-label with no placebo [2]. A 2014 review concluded these are "possible" benefits with no established efficacy [2]. A 2026 review notes MSC-derived exosomes have preclinical support only, with unresolved isolation, delivery, and safety barriers [3].
Contrast that with blood stem cell transplant (aHSCT), which is a genuine immune reset, not a fat injection. Registry data show 66-93% free of disease activity [1]. Those are different procedures with different biology.
| Approach | MS evidence | Design |
|---|---|---|
| Fat-derived MSC | No established efficacy [2] | Open-label, no controls [2] |
| Blood stem cell (aHSCT) | 66-93% disease-activity-free [1] | Registry, large [1] |
Autologous MSC therapy has been trialled in other conditions with mixed results, including a phase 2 trial where it beat placebo in atopic dermatitis [4]. That shows the cells can do something in inflammation. It does not transfer to MS.
My call: fat-derived stem cells for MS are unproven, and "great success" is a marketing phrase, not a trial result. Ask for the trial number and the published outcomes before believing any success claim. Confidence: moderate that this is not established; low on any specific Canadian program, which is not in front of me.
Sources used 4
-
Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Autologous and allogeneic HSCT, plus emerging cellular therapies, are surveyed to summarize indications, outcomes, risks, and future directions in autoimmune diseases.
DOI: 10.1038/s41409-022-01702-w -
Cell-Based Therapeutic Strategies in Multiple Sclerosis
Mesenchymal stem cell transplantation is safe and tolerable in multiple sclerosis, with early phase I/II trials showing possible functional and MRI benefits but no established efficacy.
DOI: 10.17925/enr.2014.09.01.37 -
Multicellular Exosomes as Therapeutic Modulators of Neuroinflammation: Mechanisms and Clinical Prospects
This narrative review synthesizes preclinical and mechanistic evidence that exosomes from neurons, glia, and mesenchymal stem cells modulate neuroinflammation by inhibiting pro-inflammatory cytokines, promoting anti-inflammatory cytokines, regulating immune cells, and supporting…
DOI: 10.2147/IJN.S585449 -
Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial
A multicenter, randomized, single-blind, placebo-controlled phase 2 trial demonstrates that autologous adipose tissue-derived mesenchymal stem cell (AtMSC) therapy improves disease activity (EASI, SCORAD, IGA) and reduces the Th2 biomarker TARC in adults with moderate-to-severe …
DOI: 10.1186/s13287-025-04763-y